Atyr Pharma Inc (ATYR)

Apr 03, 2025

aTyr Pharma to Participate in April Investor Conferences - GlobeNewswire

Apr 03, 2025

Apr 03, 2025

Biotech Innovator aTyr Pharma Sets Key Investor Meetings at Premier Healthcare Conferences - Stock Titan

Apr 03, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World

Apr 02, 2025

Apr 02, 2025

ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - MarketScreener

Apr 02, 2025

Mar 27, 2025

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 27, 2025

Mar 27, 2025

aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan

Mar 27, 2025

Mar 27, 2025

Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey

Mar 27, 2025

Mar 26, 2025

aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

aTyr Pharma appoints new head for efzofitimod program - Investing.com

Mar 26, 2025

Mar 26, 2025

ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener

Mar 26, 2025

Mar 26, 2025

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan

Mar 26, 2025

Mar 24, 2025

Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World

Mar 24, 2025

Mar 22, 2025

Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com

Mar 22, 2025

Mar 21, 2025

10 Hot Biotech Stocks Under $5 - Insider Monkey

Mar 21, 2025

Mar 19, 2025

Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 19, 2025

Mar 18, 2025

Atyr, FDA align on efzofitimod trial analysis for pulmonary sarcoidosis - Sarcoidosis News

Mar 18, 2025

Mar 17, 2025

aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments - Markets Insider

Mar 17, 2025

Mar 17, 2025

Reviewing Atyr PHARMA (NASDAQ:ATYR) & Windtree Therapeutics (NASDAQ:WINT) - Defense World

Mar 17, 2025

Mar 16, 2025

HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - Defense World

Mar 16, 2025

Mar 15, 2025

Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Mar 15, 2025

Mar 14, 2025

Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 14, 2025

aTyr Pharma’s Earnings Call Highlights Progress and Challenges - TipRanks

Mar 14, 2025

Mar 14, 2025

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha

Mar 14, 2025

Mar 14, 2025

Cantor Fitzgerald maintains Overweight on aTyr Pharma stock - Investing.com India

Mar 14, 2025

Mar 14, 2025

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... - Yahoo

Mar 14, 2025

Mar 14, 2025

aTyr Pharma shares fall as Q4 loss narrows - Investing.com India

Mar 14, 2025

Mar 14, 2025

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... By GuruFocus - Investing.com Canada

Mar 14, 2025

Mar 14, 2025

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising Clinical Developments - GuruFocus.com

Mar 14, 2025

Mar 14, 2025

aTyr Pharma Reports 2024 Results and Strategic Progress - TipRanks

Mar 14, 2025

Mar 13, 2025

Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations - Investing.com

Mar 13, 2025

Mar 13, 2025

aTyr Pharma Inc Reports Q4 2024 Earnings: EPS of -$0.18 Beats Es - GuruFocus.com

Mar 13, 2025

Mar 13, 2025

aTYR PHARMA INC SEC 10-K Report - TradingView

Mar 13, 2025

Mar 13, 2025

aTyr Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025

Mar 13, 2025

Atyr Pharma: Q4 Earnings Snapshot - mySA

Mar 13, 2025

Mar 13, 2025

aTyr Pharma shares fall as Q4 loss narrows By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 13, 2025

ATYR PHARMA Earnings Results: $ATYR Reports Quarterly Earnings - Nasdaq

Mar 13, 2025

Mar 13, 2025

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - The Manila Times

Mar 13, 2025

Mar 13, 2025

aTyr Pharma Hits Major Phase 3 Milestone with $94M War Chest for Sarcoidosis Drug - StockTitan

Mar 13, 2025

Mar 12, 2025

aTyr Pharma’s efzofitimod shows promise in ILD treatment By Investing.com - Investing.com Canada

Mar 12, 2025

Mar 12, 2025

aTyr Pharma’s efzofitimod shows promise in ILD treatment - Investing.com India

Mar 12, 2025

Mar 12, 2025

aTyr Pharma Announces Publication Demonstrating - GlobeNewswire

Mar 12, 2025

Mar 12, 2025

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - The Manila Times

Mar 12, 2025

Mar 12, 2025

Breakthrough: New Science Study Reveals How Efzofitimod Fights Chronic Inflammation - StockTitan

Mar 12, 2025

Mar 08, 2025

aTyr Pharma, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025

Mar 07, 2025

Atyr Pharma Shares Rise After Lung Disease Treatment Passes Safety Review - MarketWatch

Mar 07, 2025

Mar 07, 2025

aTyr Pharma: Attractive Buy Opportunity Amid Positive Phase 2 Data and Anticipated Phase 3 Catalysts - TipRanks

Mar 07, 2025

Mar 07, 2025

aTyr rises after safety update on lead program - Seeking Alpha

Mar 07, 2025

Mar 06, 2025

aTyr Pharma Announces Fourth Positive DSMB Review for - GlobeNewswire

Mar 06, 2025